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Epidemiology
Although first described in 1935, the clinical 
importance of C. difficile was not recognised until 
several patients died from fulminant colitis after 
receiving clindamycin in the 1970s. The incidence and 
severity of C. difficile has increased substantially in 
the last 20 years in the developed world. This trend 
is most prominent in elderly people in hospital and 
is increasingly recognised in residential aged-care 
facilities. In the USA, C. difficile is now the 18th leading 
cause of death in those over 65 years old.5 
There is also an increased incidence of C. difficile 
infection outside of healthcare facilities. In a targeted 
surveillance program in Victoria, 16% of C. difficile 
cases were community-associated.6 Of cases 
identified in Queensland, 37% had community-onset 
diarrhoea (unpublished data). Similarly, in surveys in 
the USA, up to 41% of cases were not associated with 
recent hospitalisation.7 
In Australia, there is no published evidence of 
increasing incidence of C. difficile infection. However, 
until recently there was no uniform diagnostic 
approach or surveillance.8 In Victoria, between 
October 2010 and March 2011 there were 370 
healthcare-associated cases (1.7 per 10 000 occupied 
bed days).6
Outbreaks of hypervirulent C. difficile
In 2005 a novel strain of C. difficile, now known 
as PCR ribotype 027, led to an outbreak of severe 
diarrhoea and markedly increased mortality in 
hospitalised patients in Quebec, Canada.9 Cases 
were significantly more likely to have received 
fluoroquinolones, in particular moxifloxacin and 
Introduction
Infection with the toxigenic anaerobe Clostridium 
difficile causes diarrhoea and colitis. Less commonly 
it causes toxic megacolon, colonic perforation and 
death. Disease is caused by two exotoxins – A and B – 
which rank among the most potent bacterial toxins 
described.1
Older people with comorbidities are more often 
infected and have a poorer outcome. Risk factors 
for C. difficile infection are listed in Box 1.2-4 With the 
emergence of hypervirulent strains associated with 
increased mortality, C. difficile has moved from an 
uncommon hospital-acquired infection to a global 
public health concern. 
C. difficile infection is closely associated with 
antimicrobial use. Consequently, any clinician who 
prescribes or dispenses antibiotics has an important 
role in preventing this potentially life-threatening and 
often avoidable infection.
SUMMARY
Clostridium difficile infection causes colitis 
and is closely associated with the use of 
antimicrobials, probably due to disruption of 
the normal bowel flora. 
Avoiding inappropriate antimicrobial use 
is the most important way to prevent this 
potentially life-threatening infection. 
Emergent hypervirulent variants of C. difficile 
are associated with increased transmission, 
morbidity and mortality and have caused 
epidemics in North America and Europe. 
Cases have also been reported in Australia 
so intensified surveillance and antimicrobial 
stewardship is more important than ever. 
While any antimicrobial can precipitate  
C. difficile, fluoroquinolones, clindamycin and 
cephalosporins are particularly implicated. 
Other drugs, such as proton pump inhibitors, 
have also been associated with an increased 
incidence of C. difficile. 
Severe disease is managed in hospital. For 
non-severe disease, treatment generally 
includes supportive measures and  
treatment with oral metronidazole. Relapse  
is common.
Controlling Clostridium difficile
Mark McFarlane
Registrar1 
Krispin Hajkowicz 
Infectious diseases 
physician1 
Senior lecturer2
1 Department of Infectious 
Diseases  
Royal Brisbane and 
Women’s Hospital
2 School of Medicine 
University of Queensland 
Brisbane
Key words
antibiotics, colitis, diarrhoea, 
infection
Aust Prescr 2013;36:121–4
First published online  
16 May 2013
Box 1    Risk factors for Clostridium difficile infection 2 *
Current or recent antimicrobial exposure (within 10 weeks)
Use of proton pump inhibitor or H2-receptor antagonist
 
Current or recent hospitalisation (within 2 months) 
Chemotherapy 
Older age 
Medical comorbidities3 
Previous C. difficile infection, especially relapsed disease
Use of diclofenac
* Up to 25% of community-acquired cases occur without established predisposing risk 
factors,4 therefore stool testing should be considered for community-acquired diarrhoea
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Antimicrobial stewardship programs using consensus 
guidelines, antimicrobial pre-approval, directed 
therapy based on culture results (where possible) 
and limiting the duration of intravenous and oral 
antimicrobials have been shown to decrease 
the incidence of C. difficile.12 The presence of an 
antimicrobial stewardship system is an Australian 
National Safety and Quality Health Service Standard.13 
Other drugs associated with  
C. difficile
Proton pump inhibitors were associated with an 
increased risk of C. difficile (approximate risk ratio 
= 1.7) in two meta-analyses.14,15 Concomitant use of 
antibiotics and proton pump inhibitors confers the 
highest risk. H2-receptor antagonists also increase the 
risk of C. difficile, but not to the same extent as proton 
pump inhibitors. Sometimes inappropriately used for 
‘peptic ulcer prophylaxis’, up to 70% of proton pump 
inhibitor use in hospitals is outside recommended 
use.16 Judicious prescribing of these drugs within 
guidelines presents another important opportunity for 
prevention of C. difficile.
C. difficile has also been associated with several 
systemic antifungals, some cancer chemotherapies 
(such as doxorubicin and 5-fluorouracil), some 
immunosuppressants (such as methotrexate and 
cyclophosphamide)17 and the non-steroidal anti-
inflammatory drug diclofenac.18 These drugs all 
disrupt normal bowel flora. 
Diagnosis
In a patient with signs and symptoms of infection, 
a single positive faecal immunoassay for toxin 
establishes the diagnosis of C. difficile. Testing should 
only be performed on an unformed stool sample. 
Different laboratories have varying testing algorithms. 
The majority of Australian laboratories perform 
enzyme immunoassays for toxins A and B.19 Combined 
assays for toxins A and B have a high specificity, but 
more limited sensitivity ranging from 60 to 90%. This 
means that a negative toxin result does not exclude 
gatifloxacin, than non-infected controls  
simultaneously admitted to the same hospital.  
PCR ribotype 027 produces additional virulence 
factors and is resistant to moxifloxacin.
There is increased transmission of PCR ribotype 027 
in healthcare settings, with many large outbreaks 
resulting in frequent colectomies and high mortality in 
North America and Europe. Isolated, locally-acquired 
cases have also been reported in Australia.10 
Antimicrobial use and C. difficile 
Previous or current antimicrobial use is the major 
risk factor for C. difficile, although a minority of 
community cases have no history of antimicrobial 
prescription.11 Infection occurs when the normal 
colonic flora is disrupted by antimicrobials. This allows 
C. difficile to colonise the lumen of the large bowel 
and cause disease. Use of virtually any antibiotic may 
lead to C. difficile infection, although clindamycin, 
fluoroquinolones, penicillin beta-lactamase inhibitor 
combinations, amoxycillin and broad-spectrum 
cephalosporins are most frequently implicated. 
Curiously, even the mainstays of treatment for  
C. difficile – metronidazole and vancomycin – can 
precipitate C. difficile infection.
Minimising the risk of infection
Avoiding inappropriate antibiotic 
therapy prevents C. difficile in individual 
patients. When antimicrobials are 
indicated, using the narrowest-spectrum 
drug for the shortest period is essential. 
Table 1 lists common clinical scenarios 
where antibiotic therapy may be 
avoided, or a narrow-spectrum drug 
selected.
Discussing the risk of C. difficile should be part of the 
consultation with any patient starting antibiotics. It 
can be raised in the difficult but common situation 
where a patient expects to be prescribed antibiotics 
when they are not indicated. 
Table 1    Minimising the risk of Clostridium difficile in common clinical situations
Presentation Intervention with risk of causing 
Clostridium difficile 
More appropriate option
Upper respiratory tract infection Amoxycillin-clavulanate Patient education, good hydration and 
simple analgesia
Mild community-acquired pneumonia Ceftriaxone Amoxycillin
Asymptomatic bacteriuria outside 
pregnancy
Cefalexin Education and reassurance
Cutaneous abscess less than 5 cm Cefalexin Incision and drainage
Non-specific dyspepsia Proton pump inhibitor Careful evaluation of risks
Avoiding inappropriate 
antibiotic therapy 
prevents C. difficile in 
individual patients
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relapses. Referral to an infectious disease specialist or 
gastroenterologist is recommended.
Ancillary treatments
Since disruption of normal flora is thought to 
be integral to the pathogenesis of infection, 
administration of probiotics to restore a symbiotic 
microbial flora has gained traction. Recent 
evidence suggests that commercially available 
probiotics containing Saccharomyces, Lactobacillus, 
Bifidobacterium and Streptococcus species moderately 
reduce the risk of relapse (relative risk 0.34). 
Probiotics containing mixed species were marginally 
more effective than monomicrobial products. 
Probiotics are well tolerated, making them particularly 
appealing.26,27
If more than one C. difficile relapse occurs and 
the patient consents, donor faecal microbiota 
infection. Submitting more than one stool sample for 
testing does not markedly improve sensitivity and is 
not recommended.20 
Polymerase chain reaction-based assays have high 
sensitivity (93–97%)21,22 and excellent specificity, 
but are expensive. Stool culture is too slow and 
laborious to be clinically useful, but is necessary to 
identify hypervirulent strains from a population health 
perspective.
Glutamate dehydrogenase stool antigen is a highly 
sensitive, but poorly specific, test for C. difficile 
infection. It is increasingly used as an initial screening 
test in a diagnostic algorithm which also includes 
toxin assays and polymerase chain reaction.23
Management
Management of infection involves supportive measures 
and specific antibiotic therapy for C. difficile. Where 
possible, any precipitating antecedent antimicrobials 
should be stopped. Although there is no evidence 
that stopping proton pump inhibitors prevents relapse 
or alters the outcome of C. difficile infection,15 they 
should be ceased if there is no strong indication. 
Antiperistaltic drugs such as opioids and loperamide 
should be avoided to reduce the risk of developing 
toxic megacolon. Oral fluid intake should be 
encouraged and rehydration solutions considered. The 
treatment of C. difficile depends on its severity. 
Non-severe disease
Mild to moderate disease can be managed outside 
of hospital (see Box 2). Oral metronidazole 400 mg 
three times a day for 10 days is recommended for an 
initial episode. In a randomised comparative study 
of patients with non-severe disease, 90% were cured 
with metronidazole and 98% with oral vancomycin. 
There was no significant statistical difference between 
treatment arms.24  
Severe disease
Severe disease requires admission to hospital  
(Table 2). Surgical consultation, fluid resuscitation, 
and oral vancomycin are recommended. Guidelines 
for managing severe disease have been produced by 
the Australasian Society for Infectious Diseases.2
Relapsing disease
Relapses of colitis are seen in up to 25% of patients 
within four weeks of the end of treatment.25 The first 
recurrence should be treated in the same way as the 
initial episode (see Box 2). Subsequent recurrences 
should not be managed with metronidazole due to 
the risk of peripheral neuropathy with prolonged 
administration. A prolonged tapered course of 
vancomycin has been suggested for multiple 
Box 2    Management of non-severe Clostridium difficile 2
General measures
Avoid or stop therapy with antiperistaltic drugs 
Stop antibiotic therapy or use a narrow-spectrum antimicrobial if possible. If not,  
a prolonged course of treatment for C. difficile may be required.
Perform serial clinical assessment and include measurements of white cell count, 
creatinine and electrolytes
Treatment of initial episode
Metronidazole 400 mg orally three times a day for 10 days
If unable to tolerate oral treatment, use metronidazole 500 mg intravenously  
8-hourly for 10 days
Treatment of first recurrence
As for initial episode
Treatment of second or subsequent recurrence
Vancomycin in a pulsed/tapering course (e.g. 125 mg orally, four times a day for  
14 days, then 125 mg twice a day for 7 days, then 125 mg every second day for  
2–8 weeks; (other regimens also described)
Extracted and modified from: Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, 
McGregor A, et al. Australasian Society for Infectious Diseases guidelines for the diagnosis 
and treatment of Clostridium difficile infection. Med J Aust 2011;194:353-358. 
© Copyright 2011. The Medical Journal of Australia – reproduced with permission.
Table 2    Features suggesting severe Clostridium difficile 
infection 2
Clinical features Laboratory Additional features
Acute abdomen
Fever >38.5° C
Hypotension 
Tachycardia 
Ileus
White blood cell count >15 x 109/L
Serum albumin <25 mg/L
Elevated blood lactate
Acute kidney injury
Toxic megacolon
Pseudomembranes on 
colonoscopy
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has not seen extensive and prolonged outbreaks 
like those in North America and Europe. To maintain 
this position, clinical suspicion in cases of antibiotic-
associated diarrhoea, recognition of community-
acquired C. difficile and rigorous infection control are 
needed. Antimicrobial stewardship programs have 
been shown to reduce the incidence of C. difficile. 
This involves the judicious use of antimicrobials for 
approved indications only, and with the narrowest 
spectrum and shortest duration possible. Appropriate 
use of proton pump inhibitors and other drugs 
associated with C. difficile will also help to prevent 
infection. Ensuring optimal prescribing will protect 
individual patients and the Australian community at 
large from this very important iatrogenic infection. 
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transplantation may be considered. In a randomised 
trial, faecal transplantation was associated with a 
substantially higher cure rate than oral vancomycin 
therapy (94% vs 31%, p<0.001).28
Monitoring response to treatment
Response to treatment is monitored with history and 
examination. The frequency of diarrhoea should start 
to decrease after about three days of treatment, and 
the patient should not have any feature of severe 
disease (fevers, rigors, peritonitis, toxic megacolon, 
ileus or haemodynamic instability). Routine follow-up  
stool examinations are not useful as a significant 
proportion of asymptomatic patients will have 
persistent stool carriage within 30 days of the end of 
treatment.2 
Conclusion
C. difficile is an emerging pathogen particularly in 
elderly people with comorbidities. So far, Australia 
D McKenzie, M Rawlins, C Del Mar. Antimicrobial stewardship: what’s it all about? 
Aust Prescr 2013;36:116-20.
New drugs: Fidaxomicin. Aust Prescr 2013;36:139-43.
FURTHER READING
SELF-TEST 
QUESTIONS
True or false? 
3. Treatment of an 
initial recurrence of 
Clostridium difficile 
should be with 
metronidazole.
4. A follow-up stool 
investigation for 
Clostridium difficile 
should be performed 
once the patient has 
recovered. 
Answers on page 143
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